Resources

Selected
  • Pneumococcal disease
Type of publications
Regions
Diseases
Methodological quality (AMSTAR 2)
270 results found
2024 ∙ Pereira, A. Pinho, C. Oliveira, A. Santos, R. Felgueiras, M. Martins, J. P.
Vaccination Promotion Strategies in the Elderly: Systematic Review and Meta-Analysis
Adults Older adults Influenza Pneumococcal disease COVID-19 Coverage
Rating:
Not applicable
2024 ∙ NACI
Recommendations on the use of pneumococcal vaccines in adults, including PNEU-C-21
Recommendation Americas Canada Adults Pneumococcal disease
Download:
2024 ∙ NIAC
Updated recommendations for pneumococcal conjugate vaccination in childhood in Ireland
Recommendation Europe Ireland Pneumococcal disease
Download:
2024 ∙ NACI
Economic Evidence Supplementary Appendix to the Recommendations for Public Health Programs on the Use of Pneumococcal Vaccines in Children, Including the Use of 15-Valent and 20-Valent Conjugate Vaccines
Background paper Americas Canada Pneumococcal disease
Download:
2024 ∙ NACI
Recommendations for public health programs on the use of pneumococcal vaccines in children, including the use of 15-valent and 20-valent conjugate vaccines
Recommendation Americas Canada Pneumococcal disease
Download:
2023 ∙ Eiden, Amanda L. Barratt, Jane Nyaku, Mawuli K.
A review of factors influencing vaccination policies and programs for older adults globally
Adults Older adults Influenza Pneumococcal disease Herpes zoster Tetanus Acceptance
Rating:
Not applicable
2023 ∙ Nagra, D. Bechman, K. Adas, M. Yang, Z. Alveyn, E. Subesinghe, S. Rutherford, A. Allen, V. Patel, S. Russell, M. D. Cope, A. Norton, S. Galloway, J.
A Systematic Review and Meta-Analysis of Anti-Rheumatic Drugs and Pneumococcal Vaccine Immunogenicity in Inflammatory Arthritis
All age groups Pneumococcal disease Efficacy/effectiveness
Rating:
Critically low
2023 ∙ Jagne, Isatou von Mollendorf, Claire Wee-Hee, Ashleigh Ortika, Belinda Satzke, Catherine Russell, Fiona M.
A systematic review of pneumococcal conjugate vaccine impact on pneumococcal nasopharyngeal colonisation density in children under 5 years of age
Newborn Children Pneumococcal disease Efficacy/effectiveness
Rating:
Low
2023 ∙ Doggen, Kris van Hoek, Albert Jan Luyten, Jeroen
Accounting for Adverse Events Following Immunization in Economic Evaluation: Systematic Review of Economic Evaluations of Pediatric Vaccines Against Pneumococcus, Rotavirus, Human Papillomavirus, Meningococcus and Measles-Mumps-Rubella-Varicella
Newborn Children Adolescents Adults Pneumococcal disease Rotavirus Human papillomavirus (HPV) Meningococcal disease Mumps Measles Rubella Economic aspects
Rating:
Not applicable
2023 ∙ Pichichero, Michael Malley, Richard Kaur, Ravinder Zagursky, Robert Anderson, Porter
Acute otitis media pneumococcal disease burden and nasopharyngeal colonization in children due to serotypes included and not included in current and new pneumococcal conjugate vaccines
Children Adolescents Pneumococcal disease Efficacy/effectiveness Efficacy/effectiveness
Rating:
Critically low
Loading...